Snežana Knežević, Jelena Vulović, Marijana Jandrić-Kočić

DOI Number
First page
Last page


Behçet's disease is a chronic relapsing vasculitis with complex immunopathogenesis that can affect multiple organs, although mucocutaneous lesions are predominantly observed. Diagnosis of Behçet's disease is challenging and relies on clinical manifestations as no specific laboratory test is available. A positive Pathergy test should raise suspicion of Behçet's disease. The authors present a clinical case of a 22-year-old woman who presented with intermittent fever, weight loss, odynophagia, dysphagia, left knee arthritis, and multiple painful oral-genital aphthosis. The patient received treatment with benzydamine hydrochloride mouthwash, lidocaine on ulcers, antibiotics, and non-steroidal anti-inflammatory drugs, but the healing process was slow, and a new disease attack occurred two months later. The Pathergy test was performed and found to be positive, prompting consultation with an immunologist and gynecologist. The patient was administered Colchicine (1.5 mg/day), which resulted in decreased symptoms, albeit with a slow healing process. During the 6-month follow-up period, the disease attack was followed by a period of remission. The evidence base for the treatment of Behçet's disease is limited, and current options include symptomatic, non-biological, and biological immunosuppressive drugs to reduce clinical manifestations. A thorough evaluation and education in primary healthcare settings are crucial to facilitate timely multidisciplinary referrals for effective management of Behçet's disease.


Primary healthcare, Behçet's disease, aphthous stomatitis, vasculitis

Full Text:



Leccese P, Alpsoy E. Behçet's Disease: An Overview of Etiopathogenesis. Front Immunol 2019; 10:1067.

Bulur I, Onder M. Behçet disease: New aspects. Clinics in Dermatology 2017; 35(5):421–34.

Alpsoy E, Bozca BC, Bilgic A. Behçet Disease: An Update for Dermatologists. Am J Clin Dermatol 2021; 22(4):477-502.

Nakamura J, Meguro A, Ishii G, Mihara T, et al. The association analysis between HLA-A*26 and Behçet's disease. Sci Rep 2019; 9(1):4426.

Vural, S, Boyvat, A. The skin in Behçet's disease: Mucocutaneous findings and differential diagnosis. JEADV Clin Pract 2022; 1:11– 20.

Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1-11.

Davatchi F, Assaad-Khalil S, Calamia KT, et al; International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28(3):338-47.

Cho SB, Zheng Z, Ahn KJ, et al. Serum IgA reactivity against GroEL of Streptococcus sanguinis and human heterogeneous nuclear ribonucleoprotein A2/B1 in patients with Behçet disease. Br J Dermatol 2013; 168(5):977-83.

Takeuchi M, Karasawa Y, Harimoto K, et al. Analysis of Th Cell-related Cytokine Production in Behçet Disease Patients with Uveitis Before and After Infliximab Treatment. Ocul Immunol Inflamm 2017; 25(1): 52-61.

Saleh Z, Arayssi T. Update on the therapy of Behçet disease. Ther Adv Chronic Dis 2014; 5:112-34.

Mat C, Yurdakul S, Sevim A, Özyazgan Y, Tüzün Y. Behçet's syndrome: facts and controversies. Clin Dermatol 2013; 31:352-61.

Ilhan B, Can M, Alibaz-Oner F, Yilmaz-Oner S, Polat-Korkmaz O, Ozen G, Mumcu G, Maradit Kremers H, Direskeneli H. Fatigue in patients with Behçet's syndrome: relationship with quality of life, depression, anxiety, disability and disease activity. Int J Rheum Dis 2018; 21(12):2139-45.

Alpsoy E. New Evidence-Based Treatment Approach in Behçet's Disease. Patholog Res Int 2012: 871019.

Bozca BC, Alpsoy E. Experimental Therapeutic Solutions for Behcet's Disease. J Exp Pharmacol 2021; 13:127-45.

Shahneh ZF, Mohammadian M, Babaloo Z, Baradaran B. New approaches in immunotherapy of behçet disease. Adv Pharm Bull 2013; 3:9-11.

Hatemi G, Yazici Y, Yazici H. Behçet’s syndrome. Rheum Dis Clin North Am 2013; 39:245-61.

Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 2018; 77:808-18.



  • There are currently no refbacks.

© University of Niš, Serbia
Creative Commons licence CC BY-NC-ND
ISSN 0354-4699 (Print)
ISSN 2406-050X (Online)